Rare disease biotech stocks pop on the news that Vinay Prasad, the FDA’s chief biologics regulator, will depart the FDA at the end of April; Sen. Ron Johnson launches an investigation into recent rare ...
Barclays 28th Annual Global Healthcare Conference March 11, 2026 8:00 AM EDTCompany ParticipantsMatthew Klein - CEO ...
A key US Republican senator said he’s launched an investigation into the Food and Drug Administration’s recent denials of ...
The senator, who has long advocated for expanding access to experimental therapies, reportedly called the FDA’s request for a sham surgery–controlled Phase 3 trial for uniQure’s Huntington’s disease ...
The MarketWatch News Department was not involved in the creation of this content. Industry veteran brings more than 30 years of experience launching therapies for neurological diseases, including ...
This will be Prasad’s second exit from the FDA during the current Trump administration. In July, he resigned amid his controversial handling of a gene therapy treatment for Duchenne muscular dystrophy ...
"The stories are so outrageous," Senator Ron Johnson said. "It just appears that they’re looking for excuses to say no." ...
FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising ...
As the population ages, the American Heart Association now projects 6 in 10 adults will have cardiovascular disease by 2050 ...
Local cost pressures and insurance gaps drive increased focus on preventive, transparent dental care options We are ...
A senior FDC official said the product is a “failed therapy” and confirmed that regulators have asked uniQure to run a new trial to prove the therapy actually helps Huntington’s patients. The ...
Recent decisions at the FDA threaten to turn its disagreements with the drugmaker UniQure into another political headache for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results